A. Fuentes-Alburo

Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer

I. Abraham, A. McBride, K. MacDonald, 2021, Journal of medical economics.

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

C. Waller, A. Fuentes-Alburo, J. Möbius, 2021, British Journal of Cancer.

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast Cancer Research and Treatment.

Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

I. Abraham, A. McBride, K. MacDonald, 2021, Journal of medical economics.

Angiogenesis in the Bone Marrow of Patients with Breast Cancer

M. Chávez-MacGregor, A. Avilés-Salas, C. Gómez-Ruíz, 2005, Clinical Cancer Research.

Angiogenesis in the BoneMarrowof Patientswith Breast Cancer

M. Chávez-MacGregor, A. Avilés-Salas, D. Green, 2005 .

Induction of p53 Up-Regulated Modulator of Apoptosis Messenger RNA by Chemotherapeutic Treatment of Locally Advanced Breast Cancer

J. Lankelma, R. Kerkhoven, P. Pohlmann, 2005, Clinical Cancer Research.

Induction of p 53 Up-Regulated Modulator of Apoptosis Messenger RNA by Chemotherapeutic Treatment of Locally Advanced Breast Cancer

J. Lankelma, R. Kerkhoven, P. Pohlmann, 2005 .